Top 10 Social Network Startup Investors in Switzerland in April 2025

Last updated: Apr 2025 A list of 10 angel investors and VC (Venture Capital) funds that invest in Social network startups based in Switzerland. We rank investors based on the number of investments they made in Social network companies from Switzerland. We update this investor list every month.

Top 10 Social Network Startup Investors in Switzerland in April 2025

Investor	Social Network Switzerland investments
Verve Ventures	3
Swiss Founders Fund	2
Sam Lim	2
SICTIC	2
FortyOne Group	1
Yttrium	1
Randstad Innovation Fund	1
Zürcher Kantonal Bank	1
Foundation for Innovation and Technology (FIT)	1
Sedo	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, France, Germany

Portfolio highlights

tozero — Truly bringing lithium-ion battery waste tozero by recovering all critical matierlas, like lithium, nickel, cobalt, manganese, and graphite.
Metafuels — Our breakthrough sustainable aviation fuel (SAF) technology, aerobrew™, will make affordable net-zero aviation a reality. The technology is innovative, highly scaleable and able to tap into future global renewable energy systems efficiently. Starting from renewable feedstocks including green hydrogen, driven by renewable electricity, andsustainably sourced CO2, for example from direct air capture, aerobrew™ provides an efficient route to large-scale production of e-kerosene, overcoming the scale up challenges and high costs of alternative e-fuels technologies. aerobrew™ is also compatible with the biogenic route whereby the carbon required for the process is derived from renewable and sustainable cellulosic biomass which, does not compete with the food chain (wood, miscanthus, etc.). With a high carbon conversion, high selectivity and a high overall SAF yield, aerobrew™ leads to attractive production economics and cost leadership. With a rapidly growing demand for SAF, aerobrew™ stands to contribute significantly to the decarbonisation of global aviation and to support the achievement of net zero 2050 targets.
Orakl Oncology — Cultivated with love by the Orakl team.

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

DPhi Space — DPhi Space is a startup that specializes in shared satellites for hosted payloads to simplify access to space. The company's flagship product, Clustergate, is a modular platform that aggregates multiple payloads—such as sensors, antennas, or cameras—into a single container, allowing them to share a satellite. This approach reduces costs andcomplexity by optimizing satellite resources. Clustergate offers built-in in-orbit computing, AI processing, and real-time data analytics, enabling businesses to deploy and manage their technology in space without requiring specialized expertise.
Retinai — RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietarytechnology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.

Sedo is a domain name and website marketplace and domain parking provider based in Cambridge, Massachusetts and Cologne, Germany. Sedo headquartered in Cologne and Boston (USA), is domain trading platform with 2 million customers and 19 million domains listed for sale. Sedo offers buyers and sellers a full suite of domain-related services, such asdomain parking, appraisals, transfers as well as marketing and promotional activities. For more information, please get in touch.